Literature DB >> 29204285

Molecular characterization of Acinetobacter baumannii isolated from Iraqi hospital environment.

I M S Al-Kadmy1, A N M Ali1, I M A Salman1, S S Khazaal1.   

Abstract

Healthcare-associated items are a common source of acquired infections, and hospital-acquired infections cause significant mortality and morbidity worldwide. Acinetobacter baumannii is the most prevalent infection-causing organism in the hospital environment. Hospital articles and objects are the main sources of infection with the ability to transmit some of the pathogenic microorganisms such as A. baumannii, which is considered a serious problem in therapeutic treatments. In the current study, we isolated A. baumannii from hospital sources and evaluated its antibiotic resistance, virulence factors and resistance gene determinants. The isolates were identified phenotypically as well as genotypically using PCR. In addition, their capability for biofilm formation and ten other virulence factors were measured. Of 112 samples, 21 showed growth of the target organism. Apart from A. baumannii, isolates of Candida albicans, Staphylococcus sp., Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae were also grown. Antibiotic susceptibility test results considered all the A. baumannii to be multidrug-resistant isolates with the highest resistance being 100% to gentamycin, ciprofloxacin; the most effective antibiotics with 100% susceptibility was colistin and tigecycline. All A. baumannii isolates had MIC for ceftriaxone >32 mg/L. All A. baumannii isolates from the hospital environment showed multidrug resistance and had many virulence factors. They have long-term resistance to dry conditions and cause a serious public health issue.

Entities:  

Keywords:  Acinetobacter baumannii; biofilm; hospital environments; multidrug-resistant biofilm

Year:  2017        PMID: 29204285      PMCID: PMC5705800          DOI: 10.1016/j.nmni.2017.10.010

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Introduction

Among the abundant bacterial pathogens, Acinetobacter baumannii is a well-known Gram-negative human pathogen in hospitals, along with Pseudomonas aeruginosa [1], [2]. The ability to gain multiple virulence factors, including resistance determinants such as serum resistance, motility, efflux pumps and iron acquisition mechanisms, help this bacterium to survive in adverse environmental conditions and facilitate the development of an infection. The ability to survive in hospital environments has helped A. baumannii to become one of the most successful nosocomial pathogens. It is responsible for infections in hospitalized patients as well as being non-pathogenic in healthy individuals [2]. The ability of this organism to develop multidrug resistance and to survive in hospital environments for prolonged periods has helped it to emerge as a successful opportunistic nosocomial pathogen [2]. Acinetobacter baumannii is widespread in clinical environments, surviving as a commensal on the skin or hair of hospital staff and patients [3] and colonizing a variety of body surfaces [4]. It is a major cause of nosocomial infections worldwide due to its remarkable propensity for the rapid acquisition of resistance to an extensive range of antimicrobial agents. Various contaminated objects have been identified that serve as potential reservoirs for this nosocomial pathogen [3], [5]. Human utility articles, importantly computers, mouse and gloves, as well as pets, have been suggested as causes for the spread of A. baumannii in humans [6]. Identification of the source or reservoir of A. baumannii strains is very important to control future infections and to curtail ongoing outbreaks. There is evidence that in the hospital environment human infectious agents or items such as mouse, computer, or gloves might carry infectious microorganisms. The production of various virulence factors varies widely among different strains from different sources, although the cause for such variation is still unclear [7], [8]. Antibiotic resistance has also been found to play a role in virulence determination [9], [10]. The present study aimed to investigate the molecular epidemiology of A. baumannii isolated from items in the hospital environment and the presence of various resistance determinants to deduce their potential ability to cause human infections.

Materials and methods

The study was conducted at Mustansiriyah University, College of Science, Department of Biology. A total of 112 samples were collected from items in the hospital environment from different Baghdad hospitals from AL-Karkh & Al-Rusafa. Each sample was washed thoroughly in PBS, and then transferred to brain–heart infusion broth for further incubation for 24 h at 37°C. The turbid broth of each sample specimen was inoculated onto appropriate plates, such as blood agar and MacConkey agar for standard aerobic growth, and placed at 37°C for 24 h or 48 h, respectively. The isolated organisms were identified using the automated system VITEK 2 (BioMérieux, Marcy l’Etoile, France). All the organisms identified as A. baumannii were used for further characterization.

Genotype confirmation of A. baumannii by PCR

The recA gene (Forward CCTGAATCTTCYGGTAAAAC/Reverse GTTTCTGGGCTGCCAAACATTAC; amplified size 240 bp) and identification of the blaOXA-51-like gene [11], [12], [13] was used for A. baumannii genotypic identification. Template DNA was prepared by the boiling method as described by Ruppé et al. [14] and supernatant was used as template DNA in PCR analyses. The amplified products were further confirmed by sequencing and BLAST matching.

Antimicrobial susceptibility testing

The MIC was found using an agar dilution method to determine the break point for A. baumanii, to the following antimicrobials, and disc diffusion was also performed (μg/disc) for: amikacin (30 μg), gentamicin (30 μg), imipenem (10 μg), norfloxacin (10 μg), azithromycin (15 μg), levofloxacin (5 μg) and amoxicillin + clavulanic acid (30 μg). Multidrug-resistance was defined as resistance to three or more antibiotics of the different classes. Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were used as positive and negative controls, respectively (CLSI 2016). MBLs were determined by EDTA disc synergy tests using meropenem and meropenem plus EDTA and the modified Hodge method. For calculation, intermediate isolates were considered as resistant.

Molecular characterization of antibiotic resistant determinants

To detect resistance determinants as given in Table 1, chromosomal DNA was extracted from the isolates and 5 μL of this extract was used for PCR assay to amplify resistance determinants using primers and conditions of amplification as previously reported [11], [15], [16], [17], [18], [19], [20], [21], [22]. Amplified products were subjected to sequencing at Microgen (Seoul, South Korea). The PCR products were analysed in horizontal electrophoresis using a 1% agarose gel and 10-kb DNA ladder (Kapa Biosystem, Cape Town, South Africa) as a molecular marker, then PCR products were visualized by UV light at 336 nm.
Table 1

Primers details used in this study

Primer namePrimer sequenceBase lengthReferences
CTX-M1C-fGACTATTCATGTTGTTGTTATTTC923[15]
CTX-M1C-RTTACAAACCGTTGGTGACG
preOXA-48-fTATATTGCATTAAGCAAGGG800[16]
preOXA-48-rCACACAAATACGCGCTAACC
VIM2-fGATGGTGTTTGGTCGCATA390[17]
VIM2-rCGAATGCGCAGCACCAG
SHV-1CGCCGGGTTATTCTTATTTGTCGC1016[17]
SHV-2TCTTTCCGATGCCGCCGCCAGTCA
CTX-M2AACTCAGAGCATTCGCCGCTCA879[18]
CTX-M2BTTATTGCATCAGAAACCGTG
CTX-M9AATGGTGACAAAGAGAGTGCAACG837[18]
CTX-M9BACAGCCCTTCGGCGATGATTC
IMP2-fGGAATAGAGTGGCTTAAYTCTC232[19]
IMP2-rCCAAACYACTASGTTATCT
TEM-1ATAAAATTCTTGAAGAC1079[20]
TEM-2TTACCAATGCTTAATCA
preNDM-fCACCTCATGTTTGAATTCGCC984[21]
preNDM-rCTCTGTCACATCGAAATCGC
Bla KPCATGTCACTGTATCGCCGTCT882[22]
Bla KPCTTACTGCCCGTTGACGCCC
cnf1-FAAGATGGAGTTTCCTATGCAGGAG498[23]
cnf1-RCATTCAGAGTCCTGCCCTCATTATT
csgA-FACTCTGACTTGACTATTACC200[23]
csgA-RAGATGCAGTCTGGTCAAC
cvaC-FCACACACAAACGGGAGCTGTT680[23]
cvaR-FCTTCCCGCAGCATAGTTCCAT
iutA-FGGCTGGACATCATGGGAACTGG300[23]
iutA-RCGTCGGGAACGGGTAGAATCG
Primers details used in this study

Virulence factor detection assays

Phenotypic detection of various virulence factors of A. baumannii isolates was performed to detect their biofilm formation, N-acyl-homoserine lactone (AHL) production, quorum-sensing synthase molecule abaI, serum resistance and PCR detection of putative virulence genes cnf1, csgA, cvaC and iutA following published protocols from literature as given below [23] (Table 1).

Biofilm formation

Biofilm production on an abiotic surface was quantified as previously described [11]. In brief, 5 mL overnight cultures of A. baumannii grown at 37°C were diluted to an optical density at 600 nm (OD600) of 0.003 in Luria–Bertani medium and 500-μL aliquots were dispensed into polystyrene tubes in triplicates. Following 24 h of incubation at 37°C, the medium was removed and the tubes were washed gently once with deionized water and stained with 1% (weight/volume) crystal violet. After washing three times with distilled water, the adherent bacteria stained with crystal violet were dissolved in 1 mL of 100% methanol and quantified by measuring OD540 [11].

PCR-based detection of virulence genes

The virulence genes cnf1, csgA, cvaC, iutA were amplified as described previously [23]. The list of primers and PCR conditions are included in Table 1. The cycling conditions were as follows: one cycle 95°C for 4 min; 30 cycles 95°C for 50 s, 58°C for 60 s, 72°C for 45 s; one cycle 72°C for 8 min.

Serum resistance assay

Serum resistance was assessed according to the protocol of Kim et al. [24]. Briefly, bacterial cells grown in TSBD medium for 14 h were washed and re-suspended in PBS to an OD600 of 1.0. Human serum from five healthy individuals was pooled and diluted in PBS to a 40% final dilution. Heat-inactivated serum was prepared by incubating the same serum at 56°C for 30 min. Bacterial suspensions were then added to human serum or heat-inactivated serum to obtain a bacterial cell concentration of 1 × 107 CFU/mL and samples were incubated at 37°C for 2 h. Viable counts were determined at 0-h and 2-h time-points in triplicates.

AHL production

Production of AHL was detected among the 21 isolates as described previously by Kumar et al. [24]. In brief, reporter strain E. coli MG4 (pKDT17) (ampicillin 100 mg/L), was used for the detection and measurement of AHLs, and AHL biosensors Chromobacterium violaceum CV026 (Luria–Bertani broth, kanamycin 20 mg/L). AHL was detected in Luria agar plates covered with 40 μL of X-Gal (20 mg/mL) by streaking 1 cm apart with reporter strains E. coli MG4 or PAO-JP2 and the strain to be tested. AHLs produced by the organisms, diffused through the agar resulting in blue colour in the reporter strain. AHLs were then extracted with equal volumes of acidified ethyl acetate from the overgrown cultures and then dried over magnesium sulphate. The extracts were resuspended in HPLC grade ethyl acetate and evaluated by thin-layer chromatography as described by Shaw et al. [25].

AHL quantification

Quantification of AHL was performed as described by Miller [26]. In brief, the supernatant culture was extracted from overnight-grown culture for β-galactosidase activity and the reporter strain was diluted 1:1 in Z buffer and assayed for β-galactosidase activity by using o-nitrophenyl-d-galactopyranoside as a substrate [26].

Detection of abaI gene producing the QS signal molecules

The abaI gene encoding an autoinducer synthase was identified by PCR using already published primers [27] Forward 5′-GTACAGTCGACGTATTTGTTGAATATTTGGG-3′ and Reverse 5′-CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC-3′ were used with the following PCR cycling parameters: initial denaturation at 94°C for 10 min followed by 30 cycles of denaturation at 94°C for 30 s, Primer annealing at 66.5°C for 30 s, primer extension at 72°C for 1 min and the final extension at 72°C for 5 min. The resulting PCR amplicon was visualized in a trans illuminator [27].

Results

During the study period, a total of 112 human objects from the hospital environment were collected, from which 21 samples were grown and identified as A. baumanii. All A. baumannii isolates were confirmed by amplification of recA and bla-like gene. The isolates were 100% resistant to ciprofloxacin, levofloxacin and trimethoprim-sulfamethoxazole. More than 90% resistance was seen to tobramycin, cefepime, ceftriaxone, tetracycline and β-lactams. Resistance to meropenem and imipenem was close to 86% (Table 2, Fig. 1). All isolates were susceptible to colistin and tigecycline and <6% were resistant to polymyxin B (Table 2). MIC50 and MIC90 values are shown in Table 3. MIC for ceftriaxone was >32 mg/L for all the isolates (Table 3). Most isolates were positive for CTMX and TEM genes, VIM and SHV were present in four and three isolates, respectively, and only one was harbouring IMP. None of isolated strains had OXA or NDM (Fig. 2).
Table 2

Antibiotic susceptibility profile of study isolates

Sample IDOrganismAntibiotic susceptibility profile
Ceftriaxone MIC (E-test)PCR results (ESBL)
GenTbCefCetImpMRPCipLevTetSxtColPBTGAmp/sul
1A.baumanniiSSRRRRRRRRSSSR>32 mg/LCTXM, TEM
2A.baumanniiRRRRRRRRRRSSSR>32 mg/LCTXM
3A.baumanniiRRRRRRRRRRSSSR>32 mg/LCTXM
4A.baumanniiRRRRRRRRRRSRSR>32 mg/LTEM, SHV, IMP
5A.baumanniiSRRRRRRRRRSSSR>32 mg/LTEM, SHV
6A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
7A.baumanniiSRRRRRRRRRSSSR>32 mg/LTEM
8A.baumanniiSRRRSSRRRRSSSR>32 mg/LCTXM, TEM
9A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM
10A.baumanniiSRSRSSRRRRSSSR>32 mg/LNEG
11A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
12A.baumanniiSRSSSSRRSRSSSS>32 mg/LNEG
13A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
14A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
15A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
16A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, SHV
17A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
18A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
19A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
20A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
21A.baumanniiSRRRRRRRRRSSSR>32 mg/LCTXM, TEM
Susceptible181213300102120211
Resistant320192018182121202101020

Abbreviations: Amp/sul, ampicillin/sulbactam; Cef, cefepime; Cet, ceftriaxone; Cip, ciprofloxacin; Col, colistin; Gen, gentamicin; Imp, imipenem; Lev, levofloxacin; MRP, meropenem; Sxt, trimethoprim/sulfamethoxazole; PB, polmyxin B; TB, tobramycin; Tet, tetracycline; TG, tigecycline.

Fig. 1

Antibiotic susceptibility profile for study isolates.

Table 3

Antibiotic susceptibility profile of study isolates with MIC50 and MIC90 value

Antibiotic familyAntibioticBreakpoints
MIC50 (mg/L)MIC90 (mg/L)Resistant (%)Susceptible (%)
SIR
AminoglycosidesGentamicin≤48≥164814.385.7
Tobramycin≤48≥16163295.24.8
CephalosporinsCefepime≤816≥32163290.59.5
Ceftriaxone≤816–32≥64163295.24.8
CarbapenemsImipenem≤24≥881685.714.3
Meropenem≤24≥881685.714.3
FluoroquinolonesCiprofloxacin≤12≥448100.00.0
Levofloxacin≤24≥8816100.00.0
TertracyclineTertracycline≤48≥1681695.24.8
Trimethoprim/sulfamethoxazoleTrimethoprim/sulfamethoxazole≤2/38NA≥4/76NA≥4/76100.00.0
FluoroquinolonesColistin≤2NA≥40.510.0100.0
Polmyxin B≤2NA≥40.514.895.2
GlycylcyclinTigecycline≤24≥80.510.0100.0
β-lactam/β -lactamase inhibitor combinationsAmpicillin/sulbactam≤8/416/8≥32/16NA≥32/1695.24.8
Fig. 2

Gel picture for PCR used in this study.

Antibiotic susceptibility profile for study isolates. Gel picture for PCR used in this study. Antibiotic susceptibility profile of study isolates Abbreviations: Amp/sul, ampicillin/sulbactam; Cef, cefepime; Cet, ceftriaxone; Cip, ciprofloxacin; Col, colistin; Gen, gentamicin; Imp, imipenem; Lev, levofloxacin; MRP, meropenem; Sxt, trimethoprim/sulfamethoxazole; PB, polmyxin B; TB, tobramycin; Tet, tetracycline; TG, tigecycline. Antibiotic susceptibility profile of study isolates with MIC50 and MIC90 value

Biofilm production

The ability of the 21 A. baumannii isolates to form biofilms was investigated and biofilm formation was compared among the different A. baumanii strains after incubation in polystyrene microtitre wells (Fig. 3). All of the clinical isolates (21/21) formed strong biofilms on abiotic surfaces. There were no weak biofilm producers in our observations.
Fig. 3

Biofilm formation in microtiter plate.

Biofilm formation in microtiter plate.

Resistance to human serum

The 21 A. baumannii strains were compared for their ability to survive the bactericidal activity of human serum. Overall, the 21 strains displayed a comparable resistance to human serum whereas the ATCC 17978 strain tested showed very low survival in the presence of human serum. All these isolates were also screened for the AHL production and 14 effectively produced AHL molecules by using the CV026 biosensor monitor system. On analysis of the biofilm-forming capabilities of the 14 isolates that produced the AHLs, they all formed strong biofilms. In this study, it has been shown that among the 21 biofilm-forming isolates, only 14 produced AHLs (Fig. 4).
Fig. 4

Production of AHLs for study isolates.

Production of AHLs for study isolates.

PCR-based detection of virulence genes and QS-producing abaI

Table 4 shows the distribution of the putative virulence genes among the 21 A. baumannii strains isolated in this study. Overall, csga (14/21) and cnf1 (10/21) were the most commonly detected virulence genes. CvaC and iutA genes were identified in 2/21 and 5/21 strains, respectively.
Table 4

PCR-based detection of virulence genes and QS producing abaI

Sample/S.NoBiofilmAHL productionSerum resitanceCnf+CsgACvaCIutAabaI
1+++++++
2+++
3+++++++
4++++++
5++
6++++
7+++++
8+++++
9+++++++
10++++
11++++++
12+++++
13+++++
14++
15+++++
16+++++
17+++++
18++++
19+++
20+++++++
21++++
PCR-based detection of virulence genes and QS producing abaI PCR for the abaI gene produced amplicons of 382 bp in 14/21 isolates that produced the QS signal molecules.

Discussion

Acinetobacter baumannii is widespread in clinical environments, surviving as commensals on the skin of hospital staff and patients, being especially concentrated in moist regions such as axilla, groin and fingertips of personnel [1], [3]. The current study proved that items in the hospital environment were sources for infections. The ability to survive in hospital environments has assisted A. baumannii to emerge as one of the most successful nosocomial pathogens and enhanced its capability to become the leading pathogen in intensive care units due to its increasing multidrug resistance. Acinetobacter baumannii has become a threat in hospitals with its rapid emergence as a resistant organism through antibiotic pressure. It grows as a nosocomial because it can develop and survive in hospital environments for prolonged periods as a result of its exceptional ability to produce highly resistant biofilms [2], [4]. Positive culture results from hospital samples showed the diversity of bacterial isolates: two Candida albicans, 11 Staphylococcus sp., five Pseudomonas aeruginosa and one isolate of Klebsiella pneumoniae were also recovered. This study found that 21 samples showed the presence of A. baumannii, more than any other organism isolated. The samples were sourced from commonly used items in the hospitals, which provide a route for the spread of infections to various categories of hospital staff. The results of antibiotic susceptibility testing showed a high level of resistance against most antibiotics, making it a multidrug-resistant bacterium. Though initially considered to be an organism of low virulence, A. baumannii is gradually gaining virulence [8], [9], [10] and this study revealed that each isolate had more than one virulence factor (Table 4). All the isolates had biofilm forming ability and were negative in gelatinase and protease reactions. Most isolates were capsulated and found to be positive in twitching motility and as pellicle producers. These virulence factors play a significant role in resistance to defence mechanisms. Moreover, A. baumannii is able to cause a wide range of infections, is increasingly resistant to antibiotics and may be associated with high mortality rates in some patients. Its virulence factors and pathogenicity mechanisms were largely unknown, and genetics study are still limited for this bacterium. In this study we showed 100% of our isolates producing biofilms. All strains were screened for AHL QS signal molecule production but only 66% of strains effectively produced AHL molecules by using the CV026 biosensor monitor system. Identification of AHLs in A. baumannii is important due to increasing nosocomial infections and because the QS cascades are possible drug target factors for future therapies to combat A. baumannii infections. We showed that among the 21 biofilm-forming isolates, only 14 produced AHLs, which may be because biofilm formation is a multifactorial event involving a number of molecules in which QS signals are one of the factors [27]. We also tried to identify the types of AHLs produced using TLC and two biosensor strains, C. violaceum CV026 and Agrobacterium tumefaciens A136. Chromobacterium violaceum strain CV026 is a violacein and AHL-negative double mini Tn5 mutant strain with transposons inserted into the CviI AHL synthase gene and violacein repressor gene. This strain produces the pigment violacein by using the exogenous AHL and detects C4 to C8-homoserine lactones (HSLs) but most strongly C6-HSL [28]. All the 14 strains that produced AHLs were found to be C6-HSL type by development with the biosensor C. violaceum CV026. Even though the biosensor strain used in this study detects a wide range of exogenous AHLs (C4- to C8-HSLs) we identified only the C6-HSL type of AHL in all 14 isolates. The negative results may be due to no/low production of AHL signals by these strains. This method of screening is rapid and easy to perform in clinical laboratories. Moreover, this method can be used to screen strains for AHL production directly from patient samples. Quantification of β-galactosidase activity showed production of variable levels of AHLs by A. baumannii, indicating the difference in source and amounts of AHLs, which may be due to differences in AHL production between strains. We also identified an autoinducer synthase gene in A. baumanii, similar to the members of the LuxI family, designated as abaI among the 21 A. baumanii strains. But abaI was identified in only 66% of A. baumanii that produced the AHLs phenotypically. This approach can be exploited for detection of QS signal molecules directly from patient samples with the presence of pathogen [28]. Csga, cnf1, cvaC and iutA virulence genes were prevalent among the A. baumannii strains of our clinical infections. Overall, csga, cnf1, cvaC and iutA virulence genes were detected in 66.7%, 47.6%, 9.5% and 23.8% of strains respectively. Previous reports demonstrated total prevalence of csga, cnf1, cvaC and iutA virulence genes among urinary tract infection samples to be 55%, 40%, 10% and 30%, respectively, which is similar to our results. In contrast, Momtaz et al. [29] reported that the prevalences of csga, cnf1, cvaC and iutA virulence genes from Iran were 12.39%, 35.53%, 21.48% and 19%, respectively, which was slightly lower than our results. These genes are the most common causes of adhesion and invasion of A. baumanni to the epithelial cells of the human organs [23]. In conclusion, we identified highly resistant and virulent strains of A. baumannii from the hospital environment in different hospitals in Baghdad. We observed strains with multifactorial phenotypes related to pathogenesis, such as biofilm formation, motility and resistance to human serum, suggesting the ability to persist, which accounts for A. baumannii survival in the hospital setting and, ultimately, for its ability to cause outbreaks of infection [8]. The most commonly detected virulence genes were csga and cnf1. The result of this study also found evidence for antibiotic resistance mediated through various genes in A. baumannii from hospital environments. Rational use of antibiotics according to the results of disc diffusion studies can help to decrease the prevalence of resistance [23]. Studies on identification of resistance gene transfer through plasmids or insertion elements, which can further deduce their probable mode of transfer [30], is required. Such information may help us to control and eradicate persistent endemic and epidemic clones of A. baumannii. In addition, rigorous infection control measures including defensive measures to prevent the propagation of plasmid resistance determinants in environments, can prevent further spread of resistance.

Conflict of Interest

Authors have nothing to disclose.
  25 in total

1.  Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases.

Authors:  Matthew J Ellington; James Kistler; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2006-12-21       Impact factor: 5.790

Review 2.  The epidemiology and control of Acinetobacter baumannii in health care facilities.

Authors:  Pierre Edouard Fournier; Hervé Richet
Journal:  Clin Infect Dis       Date:  2006-01-26       Impact factor: 9.079

3.  OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins.

Authors:  Laurent Poirel; Mariana Castanheira; Amélie Carrër; Carla Parada Rodriguez; Ronald N Jones; Jorgelina Smayevsky; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

4.  Multiple FadD acyl-CoA synthetases contribute to differential fatty acid degradation and virulence in Pseudomonas aeruginosa.

Authors:  Yun Kang; Jan Zarzycki-Siek; Chad B Walton; Michael H Norris; Tung T Hoang
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

5.  Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital.

Authors:  Lemuel L Dent; Dana R Marshall; Siddharth Pratap; Robert B Hulette
Journal:  BMC Infect Dis       Date:  2010-07-07       Impact factor: 3.090

Review 6.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

7.  Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins.

Authors:  Sang Woo Kim; Chul Hee Choi; Dong Chan Moon; Jong Sook Jin; Jung Hwa Lee; Ji-Hyun Shin; Jung Min Kim; Yoo Chul Lee; Sung Yong Seol; Dong Taek Cho; Je Chul Lee
Journal:  FEMS Microbiol Lett       Date:  2009-10-13       Impact factor: 2.742

8.  The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia.

Authors:  Matthieu Eveillard; Christophe Soltner; Marie Kempf; Jean-Paul Saint-André; Carole Lemarié; Catherine Randrianarivelo; Harald Seifert; Michel Wolff; Marie-Laure Joly-Guillou
Journal:  J Infect       Date:  2009-09-11       Impact factor: 6.072

9.  Detection of quorum sensing signal molecules and identification of an autoinducer synthase gene among biofilm forming clinical isolates of Acinetobacter spp.

Authors:  Deepa Anbazhagan; Marzida Mansor; Gracie Ong Siok Yan; Mohd Yasim Md Yusof; Hamimah Hassan; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

10.  Acinetobacter baumannii in human body louse.

Authors:  Bernard La Scola; Didier Raoult
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

View more
  7 in total

Review 1.  Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review.

Authors:  Nadheema Hammood Hussein; Israa M S Al-Kadmy; Butheina Mohammed Taha; Jumaah Dakel Hussein
Journal:  Mol Biol Rep       Date:  2021-04-10       Impact factor: 2.316

2.  Occurrence of blaTEM and blaCTXM Genes and Biofilm-Forming Ability among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii in Yaoundé, Cameroon.

Authors:  Estelle Longla Madaha; Hortense Kamga Gonsu; Rhoda Nsen Bughe; Marie Christine Fonkoua; Collins Njie Ateba; Wilfred Fon Mbacham
Journal:  Microorganisms       Date:  2020-05-11

3.  Seasonal Shift in Physicochemical Factors Revealed the Ecological Variables that Modulate the Density of Acinetobacter Species in Freshwater Resources.

Authors:  M A Adewoyin; A I Okoh
Journal:  Int J Environ Res Public Health       Date:  2020-05-21       Impact factor: 3.390

4.  Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolates from Northern Africa and the Middle East.

Authors:  Paul G Higgins; Ralf Matthias Hagen; Bernd Kreikemeyer; Philipp Warnke; Andreas Podbielski; Hagen Frickmann; Ulrike Loderstädt
Journal:  Antibiotics (Basel)       Date:  2021-03-11

Review 5.  Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.

Authors:  Susan Ibrahim; Nadal Al-Saryi; Israa M S Al-Kadmy; Sarah Naji Aziz
Journal:  Mol Biol Rep       Date:  2021-08-30       Impact factor: 2.316

Review 6.  Emerging Status of Multidrug-Resistant Bacteria and Fungi in the Arabian Peninsula.

Authors:  J Francis Borgio; Alia Saeed Rasdan; Bayan Sonbol; Galyah Alhamid; Noor B Almandil; Sayed AbdulAzeez
Journal:  Biology (Basel)       Date:  2021-11-06

7.  Detection of csgA gene in carbapenem-resistant Acinetobacter baumannii strains and targeting with Ocimum sanctum biocompounds.

Authors:  Saishree R Anchana; Smiline A S Girija; Shoba Gunasekaran; Vijayashree J Priyadharsini
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.